Tumor Biology

, Volume 36, Issue 1, pp 271–278 | Cite as

Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer

  • Yufeng Huang
  • Yiqian Liu
  • Lijiang Yu
  • Jing Chen
  • Juan Hou
  • Lihua Cui
  • De Ma
  • Wangkun Lu
Research Article


Histone demethylase KDM2A has been reported to be dysregulated in lung cancer. However, its function in gastric cancer remains poorly understood. Here, it was found that the expression level of KDM2A was increased in gastric cancer tissues. Moreover, forced expression of KDM2A in gastric cancer cells promoted cell growth and migration, while the knockdown expression of KDM2A inhibited the tumorigenicity of gastric cancer cells. Mechanistically, KDM2A regulated the growth and motility of gastric cancer cells through downregulating the expression of programmed cell death 4 (PDCD4), a known tumor suppressor in the progression of gastric cancer. Taken together, our study suggested that upregulation of KDM2A was very important in the progression of gastric cancer, and KDM2A might be a promising therapeutic target.


Gastric cancer KDM2A PDCD4 Cell proliferation and migration 


Conflicts of interest



  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Lu YF, Liu ZC, Li ZH, et al. Esophageal/gastric cancer screening in high-risk populations in Henan Province, China. Asian Pac J Cancer Prev. 2013;15(3):1419–22.CrossRefGoogle Scholar
  3. 3.
    Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med. 2008;47(12):1077–83.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mason MJ, Fan G, Plath K, Zhou Q, Horvath S. Signed weighted gene co-expression network analysis of transcriptional regulation in murine embryonic stem cells. BMC Genomics. 2009;10:327.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shehin SE, Stephenson RO, Greenlee WF. Transcriptional regulation of the human CYP1B1 gene. Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression. J Biol Chem. 2000;275(10):6770–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Steger K. Transcriptional and translational regulation of gene expression in haploid spermatids. Anat Embryol. 1999;199(6):471–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Grant S. Targeting histone demethylases in cancer therapy. Clin Cancer Res. 2009;15(23):7111–3.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kampranis SC, Tsichlis PN. Histone demethylases and cancer. Adv Cancer Res. 2009;102:103–69.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kim JH, Sharma A, Dhar SS, et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res. 2012;74(6):1705–17.CrossRefGoogle Scholar
  10. 10.
    Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2013;42(2):181–5.CrossRefGoogle Scholar
  11. 11.
    Yamamoto S, Tateishi K, Kudo Y, et al. Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. Carcinogenesis. 2013;34(10):2380–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Suzuki T, Ozasa H, Itoh Y, et al. Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. J Med Chem. 2013;56(18):7222–31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Dhar SS, Alam H, Li N, et al. Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. J Biol Chem. 2012;289(11):7483–96.CrossRefGoogle Scholar
  14. 14.
    Wagner KW, Alam H, Dhar SS, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 2014;123(12):5231–46.CrossRefGoogle Scholar
  15. 15.
    Tanaka Y, Okamoto K, Teye K, et al. JmjC enzyme KDM2A is a regulator of rRNA transcription in response to starvation. EMBO J. 2013;29(9):1510–22.CrossRefGoogle Scholar
  16. 16.
    Lu T, Jackson MW, Singhi AD, et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci U S A. 2009;106(38):16339–1644.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lu T, Yang M, Huang DB, et al. Role of lysine methylation of NF-kappaB in differential gene regulation. Proc Natl Acad Sci U S A. 2012;110(33):13510–5.CrossRefGoogle Scholar
  18. 18.
    Du J, Ma Y, Ma P, Wang S, Fan Z. Demethylation of epiregulin gene by histone demethylase FBXL11 and BCL6 corepressor inhibits osteo/dentinogenic differentiation. Stem Cells. 2012;31(1):126–36.CrossRefGoogle Scholar
  19. 19.
    Ge R, Wang Z, Zeng Q, Xu X, Olumi AF. F-box protein 10, an NF-kappaB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ. 2012;18(7):1184–95.CrossRefGoogle Scholar
  20. 20.
    Lu T, Jackson MW, Wang B, et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A. 2012;107(1):46–51.CrossRefGoogle Scholar
  21. 21.
    Soejima H, Miyoshi O, Yoshinaga H, et al. Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet. 1999;87(1–2):113–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Wei NA, Liu SS, Leung TH, et al. Loss of programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer. 2009;8:70.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wei ZT, Zhang X, Wang XY, et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci. 2009;100(8):1408–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283(2):1026–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999;49(12):1067–77.CrossRefPubMedGoogle Scholar
  26. 26.
    Kalinichenko SV, Kopantzev EP, Korobko EV, et al. Pdcd4 protein and mRNA level alterations do not correlate in human lung tumors. Lung Cancer. 2008;62(2):173–80.CrossRefPubMedGoogle Scholar
  27. 27.
    Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 2003;200(5):640–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene. 2004;23(49):8135–45.CrossRefPubMedGoogle Scholar
  29. 29.
    Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21 (Waf1/Cip1). Am J Physiol Cell Physiol. 2004;287(6):C1541–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang Z, DuBois RN. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene. 2001;20(33):4450–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang W, Zhao J, Wang H, et al. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression. Exp Cell Res. 2012;316(15):2456–64.CrossRefGoogle Scholar
  32. 32.
    Zhang S, Li J, Jiang Y, Xu Y, Qin C. Programmed cell death 4 (PDCD4) suppresses metastastic potential of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2009;28:71.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Meng F, Sun G, Zhong M, Yu Y, Brewer MA. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. Int J Oncol. 2012;43(2):495–502.Google Scholar
  34. 34.
    Lu Y, Chang Q, Zhang Y, et al. Lung cancer-associated JmjC domain protein mdig suppresses formation of tri-methyl lysine 9 of histone H3. Cell Cycle. 2009;8(13):2101–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Tu H, Sun H, Lin Y, et al. Oxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR-21. Curr Pharm Des. 2012;20(11):1917–23.CrossRefGoogle Scholar
  36. 36.
    Guo PT, Yang D, Sun Z, Xu HM. PDCD4 functions as a suppressor for pT2a and pT2b stage gastric cancer. Oncol Rep. 2012;29(3):1007–12.Google Scholar
  37. 37.
    Wang WQ, Zhang H, Wang HB, et al. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway. Mol Diagn Ther. 2012;14(3):155–61.CrossRefGoogle Scholar
  38. 38.
    Motoyama K, Inoue H, Mimori K, et al. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol. 2012;36(5):1089–95.Google Scholar
  39. 39.
    Yao Q, Xu H, Zhang QQ, Zhou H, Qu LH. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun. 2009;388(3):539–42.CrossRefPubMedGoogle Scholar
  40. 40.
    Chen Y, Liu W, Chao T, et al. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett. 2008;272(2):197–205.CrossRefPubMedGoogle Scholar
  41. 41.
    Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128–36.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yufeng Huang
    • 1
  • Yiqian Liu
    • 2
  • Lijiang Yu
    • 1
  • Jing Chen
    • 3
  • Juan Hou
    • 1
  • Lihua Cui
    • 1
  • De Ma
    • 1
  • Wangkun Lu
    • 1
  1. 1.Department of OncologyJingjiang People’s HospitalJingjiangPeople’s Republic of China
  2. 2.Department of OncologyFirst Affiliated Hospital of Nanjing Medical UniversityNanjingPeople’s Republic of China
  3. 3.Department of PathologyJingjiang People’s HospitalJingjiangPeople’s Republic of China

Personalised recommendations